Drugs
Flu be gone!
Two new anti-flu drugs just hit the market and will be backed by millions in advertising. But do they work?
It’s easy to recognize the familiar signs and sensations of flu season — the hacking cough, the jackhammer headache, the mind-melting fever and the empty office cubicles. But this year there’s a new seasonal symptom — advertising.
Two pharmaceutical giants, Glaxo Wellcome and Roche, are launching massive campaigns to get Americans to shell out millions for new anti-flu remedies. But some of the scientists who have examined the drugs are skeptical they will do much more than fatten drug industry profits.
Each year from November to April, the influenza virus sickens up to 50 million Americans. As common infectious diseases go, it’s a bad one. Healthy adults need about a week to emerge from the flu’s boggy grip, and it kills about 20,000 sickly and elderly Americans each winter. Flu is also an enemy of the state in that it undercuts our efficiency — costing $5 billion in lost work and hospital bills each season, according to the CDC.
Influenza’s evolutionary strategy makes it easy to anthropomorphize as a Bill Gates among bugs — brilliant, devious and sinister. There are dozens of varieties of flu and they mutate faster than Dennis Rodman’s hair. Now and again, the molecular roulette wheel brings forth a pandemic strain unrecognizable to human immune systems; the worst of these was the 1918 virus that killed half a million Americans and 20 million souls worldwide.
Flu shots can be more or less effective protection, depending on whether the scientists who prepare the year’s batch of vaccine correctly predict which strains will predominate in the population. The Clinton administration has advocated inoculation religiously, and this year 90 million Americans are expected to bare arms for the shot — compared with 20 million a year ago.
But until now, once you got the flu the only recourse was to stay in bed with a wet washcloth and a cheesy novel nearby. This year, what passes for a cure has found its way to the market.
The new medications, Glaxo Wellcome’s Relenza and Roche’s Tamiflu, are the first in a class of drugs called neurominidase inhibitors. They work by neutralizing proteins on the viral surface that help the bug emerge from lung cells to replicate. If you haven’t heard of Relenza and Tamiflu, $50 million says you will soon — the two companies are estimated to be spending that amount to promote their drugs.
Obviously $50 million buys a lot of hype, and depending on how you look
at it, hype may be the biggest ingredient in these drugs, which cost about $50 each for a five-day therapeutic course.
Glaxo’s TV ads, produced by Saatchi and Saatchi, started airing last week. They star fat, obnoxious Wayne Knight (Newman from “Seinfeld”) as the flu — an unwanted guest who arrives at your house by bus.
The ad is intended to produce a vaguely uneasy feeling and send you reaching for the phone to get your doctor to write out a prophylactic prescription. But examining Relenza’s trek through the regulatory system produces an equally queasy feeling, akin to seeing an important public figure unclothed — an emperor, say, or perhaps Wayne Knight himself.
Consider this: The British and French medical establishments have
already rejected Relenza as an essentially worthless drug. Despite much gnashing of the teeth by Glaxo Wellcome executives, who accused the British government of trying to destroy the country’s pharmaceutical industry, Britain’s National Institute of Clinical Excellence voted last month against including Relenza on the National Health Service’s formulary.
In February, an expert panel asked by the FDA to offer a verdict on whether it should approve Relenza came to essentially the same decision as the French and British doctors.
“I wasn’t convinced by the data,” says Edwin D. Kilbourne, a renowned New York virologist who served on the advisory committee, which voted 13-4 against Relenza.
Glaxo Wellcome had presented the panel with data from three trials involving a total of 1,609 patients in Europe, Australia and North America. By Glaxo Wellcome’s analysis, the drug shaved up to two and a half days off a seven-day flu if the medication were taken within two days of the appearance of flu symptoms.
But there were some major catches. In the North American study, by far the largest, Relenza reduced the average duration of a flu case by only a day. When the FDA’s statistician got through with the data, it looked more like half a day. And Kilbourne — a scientist who is enthusiastic about the eventual deployment of an anti-neurominidase drug — found even that misleading.
“In terms of the acute symptoms — incapacitation and fever — flu
is a three- to four-day disease,” he says. “So to say this drug reduces a seven-day illness to a six-day illness, when the symptoms at the end are rather trivial, is to make somewhat unfair claims of efficacy.”
Furthermore, how many people could be expected to get to a doctor,
get proper diagnosis of flu, and get the drug within the relevant 48 hours after the first symptoms? “Depressingly few,” says Alan Sanders, an infectious disease specialist in Albany, N.Y.
Much to the astonishment of Kilbourne and other scientists, the FDA in July decided to ignore its panel’s advice and approve the drug anyway. The July 26 approval memorandum from Heidi M. Jolson, director of the FDA’s division of antiviral drug products, makes it clear she wasn’t particularly impressed by Relenza. Glaxo’s U.S./Canada study “was inconclusive in providing definitive evidence of efficacy,” she writes.
Despite this, FDA officials seem to have given the thumbs up to Relenza and
Tamiflu — which is even newer and more untested than Relenza — for
another public health reason: The next time there’s a flu pandemic, we need to have tested drugs available. And the only way to test these particular drugs is to give them a wider public outing than the clinical trials permitted.
Relenza, writes Jolson, “will offer an alternative therapeutic approach for an important public health problem.” Adds CDC flu honcho Nancy Cox, in an Oct. 28 editorial in the New England Journal of Medicine, “Patients, clinicians and the public health community alike will be fortunate to have these new drugs. Now we must determine how they may best be used.”
“I suppose the FDA felt there were so few drugs available that any drug was better than nothing,” comments Kilbourne. “I don’t think that’s an adequate answer.”
One issue the advisory panel agreed upon, which surely played a role in the FDA’s decision, was the good safety profile of Relenza. (Although Relenza did appear to temporarily reduce the lung function of some asthmatics who used it, the company has put a warning label on its product, a dry powder inhaled via a spaceship-shaped device.)
The FDA could more easily make guinea pigs of the public knowing that the drug was harmless — even if it was also worthless.
That said, early tests have shown that Tamiflu, which comes in a pill, produced vomiting twice as often as the placebo.
Still, the drugs will certainly work for some people. The most encouraging
use, though not the one listed on the drugs’ labels, is as prophylaxis for
family members of a flu patient. And the new medications may have the side benefit of lowering antibiotic use, which always increases in flu season and which contributes to the harrowing threat of antibiotic resistance.
“By treating people with something that makes them feel better a day or two earlier we’ll be prescribing fewer antibiotics,” predicts Sanders, the infectious disease specialist. “People want to leave the doctor’s office with something and in this country that something is usually antibiotics. Now the doctors have something in their armamentarium specifically for flu.”
And what about the problem of viral resistance? No one seems particularly worried about it — yet. The flu virus is constantly evolving anyway, and there’s no indication the neuraminidase inhibitors will promote the kind of radical genetic shift that would produce a pandemic virus.
“I don’t see a problem of resistance with Relenza,” says Kilbourne with a chuckle. “Most of the viruses are apparently fit enough to resist it already.”
The next pandemic is what really worries flu scientists. They know it’s coming; they don’t know when, or from where.
In 1976, in an episode recounted in New York Times reporter Gina Kolata’s new book, “Flu,” a healthy soldier’s death at Fort Dix, N.J., sent government officials into the panicked conviction they had a pandemic on their hands — from a flu virus that originated in pigs.
They began a massive vaccination campaign for a swine flu epidemic that
never came. It ended up also costing the government billions of dollars in payments to people who believed the shots gave them a crippling autoimmune disorder called Guillain-Barré syndrome.
Let’s hope the FDA’s apparently hasty approval of Relenza doesn’t have
such a sad ending.
Arthur Allen writes on health, science and other issues for Salon. He lives in Washington. More Arthur Allen.
Pick of the week: An early-’60s hipster time capsule
Pick of the week: Shirley Clarke's once-banned "The Connection" is a lean, mean saga of jazz, junk and rebellion
A time capsule loaded with smack from the bohemian underbelly of JFK-era America, Shirley Clarke’s 1961 film “The Connection” is an illustration of how much things change, and how much they stay the same. I’d be stretching to call “The Connection” a great film — it’s mannered and edgy, in a way that’s partly deliberate but also distinctive to its period — but it’s an important one in cultural and historic terms, despite being largely unknown. Watching this ensemble drama about a multiracial group of New York jazz musicians and beat philosophers in a run-down apartment, waiting for their drug dealer to show up, is like traveling back 50 years in time, only to encounter the same people you might meet on the street today (at least, in certain neighborhoods of Brooklyn, San Francisco, Austin and so on). At one point, the characters even debate the illusory distinctions between “hipsters” and “squares.”
Continue Reading CloseDrug-personality misconceptions
Alcoholic writers? Coke-head stockbrokers? The links between personality type and addiction are largely overblown
Ernest Hemingway (Credit: John F. Kennedy Presidential Library & Museum) Here’s Ernest Hemingway, dead drunk on a stool in Cuba with his face on his hand and his hand on an ever-present mojito. He’s the tormented writer, hard at work at the daily scrubbing of his sins. Like the Hard-Drinking Writer, we’ve come to expect certain personality types to have certain habits: The Morose Musician with Keith Richards’ appetite for heroin; the Insecure Starlet with Marilyn’s taste for pills; the Monomaniacal Money Manager with a nose for cocaine. They are generalizations that have been imprinted by generations of popular culture. But the types don’t necessarily line up.
Continue Reading CloseFormer neuroscientist Jacqueline Detwiler edits a travel magazine by day, but moonlights as a science writer. Her work has appeared in Wired, Men's Health, Fitness and Forbes. More Jacqueline Detwiler.
My suburban pot secret
I thought starting my own medical marijuana operation would be easy and safe. Then the DEA crackdown started VIDEO
(Credit: Yellowj via Shutterstock) It was sometime around 2 a.m. when I heard the car doors slam. I live on a very quiet street in Fort Collins, Colo., surrounded by working families who are usually falling asleep under the blue glow of their TVs by 10 p.m., and any noise in the night usually means that something is about to happen. And on that night I was certain it was about to happen to me.
Six marijuana plants were growing in my basement and because of shortsighted planning on my part, their odor had gotten completely out of control. Having never grown pot before, I foolishly overlooked the prominent admonitions printed in every growing guide I relied upon to help me with my harvest, that odor control was of the utmost importance. But equipment designed to mask the smell (ozone generators, activated carbon filters) is expensive. How much stench could six little plants really produce? I remember thinking. Well, a lot.
Continue Reading CloseGreg Campbell's new book is called "Pot, Inc.: Inside Medical Marijuana, America's Most Outlaw Industry." He is the author of "Flawless: Inside the Largest Diamond Heist in History," "Blood Diamonds: Tracing the Deadly Path of the World's Most Precious Stones" (the source material for the Leonardo DiCaprio movie of the same name) and "The Road to Kosovo: A Balkan Diary." Campbell is also an award-winning journalist whose his writing has appeared in The Wall Street Journal Magazine, The Economist, The San Francisco Times, Paris Match, and The Christian Science Monitor, among others. He lives in Fort Collins, CO. More Greg Campbell.
America’s pill-popping capital
Welcome to Kermit, W.Va. -- ground zero of the prescription drug epidemic
(Credit: iStockphoto/Salon) KERMIT, W.Va. — It takes less than a minute to drive past Kermit, five to tour the place entirely. An old coal mining town with barely 300 residents and one blinking light between the train tracks, Kermit has no supermarket, no clothing store, no main drag. Main Street is really a side street with rows of cottages, its biggest building, the Kermit community center, empty and boarded.
Yet in this tiny town, the Kermit Sav-Rite Pharmacy used to be as busy as a New York deli. Six employees worked the counter, lines at the drive-through window snaked around the square cinder-block building, and the parking lot was full day and night.
Continue Reading CloseEvelyn Nieves, former staff writer and columnist for the New York Times, is working on a book. More Evelyn Nieves.
Recovery’s new poster boy
Bill Clegg's first addiction memoir shocked readers. We talk to him about his follow-up -- and his newfound fame
Bill Clegg (Credit: Brigitte Lacombe/Little, Brown & Co.) Two years ago, Bill Clegg’s first memoir dropped like a bombshell on the New York media world. “Portrait of an Addict as a Young Man” chronicled the handsome and hugely successful book agent’s descent into a harrowing crack addiction that cost him his career, his boyfriend and his savings — and left him broke and in rehab. In one harrowing part of the book (excerpted in New York magazine) Clegg decides to blow off a first-class flight to Berlin after a week without sleep for a crack binge and sex with the cabbie driving him to his airport hotel. Staring at his pile of drugs, he wrote, “I wonder if somewhere in that pile is the crumb that will bring on a heart attack or stroke or seizure. The cardiac event that will deliver all this to an abrupt and welcome halt.”
Continue Reading Close
Thomas Rogers is Salon's Arts Editor. More Thomas Rogers.
Page 1 of 70 in Drugs
